» Articles » PMID: 28990786

Longitudinal Monitoring of Antibody Responses Against Tumor Cells Using Magneto-nanosensors with a Nanoliter of Blood

Overview
Journal Nano Lett
Specialty Biotechnology
Date 2017 Oct 10
PMID 28990786
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Each immunoglobulin isotype has unique immune effector functions. The contribution of these functions in the elimination of pathogens and tumors can be determined by monitoring quantitative temporal changes in isotype levels. Here, we developed a novel technique using magneto-nanosensors based on the effect of giant magnetoresistance (GMR) for longitudinal monitoring of total and antigen-specific isotype levels with high precision, using as little as 1 nL of serum. Combining in vitro serologic measurements with in vivo imaging techniques, we investigated the role of the antibody response in the regression of firefly luciferase (FL)-labeled lymphoma cells in spleen, kidney, and lymph nodes in a syngeneic Burkitt's lymphoma mouse model. Regression status was determined by whole body bioluminescent imaging (BLI). The magneto-nanosensors revealed that anti-FL IgG2a and total IgG2a were elevated and sustained in regression mice compared to non-regression mice (p < 0.05). This platform shows promise for monitoring immunotherapy, vaccination, and autoimmunity.

Citing Articles

Manipulating nanoliter fluid circuits on an all-glass chip by the magnetic field.

Peng X, Peng L, Guo Y iScience. 2023; 26(9):107659.

PMID: 37680486 PMC: 10481363. DOI: 10.1016/j.isci.2023.107659.


Magnetic supercluster particles for highly sensitive magnetic biosensing of proteins.

Kim S, Kim J, Im J, Kim M, Kim T, Wang S Mikrochim Acta. 2022; 189(7):256.

PMID: 35697882 PMC: 9192248. DOI: 10.1007/s00604-022-05354-x.


Advances in microfluidic extracellular vesicle analysis for cancer diagnostics.

Cheng S, Li Y, Yan H, Wen Y, Zhou X, Friedman L Lab Chip. 2021; 21(17):3219-3243.

PMID: 34352059 PMC: 8387453. DOI: 10.1039/d1lc00443c.


Risk assessment for indeterminate pulmonary nodules using a novel, plasma-protein based biomarker assay.

Trivedi N, Arjomandi M, Brown J, Rubenstein T, Rostykus A, Esposito S Biomed Res Clin Pract. 2020; 3(4).

PMID: 32913898 PMC: 7480946. DOI: 10.15761/brcp.1000173.


Noninvasive biomarkers for lung cancer diagnosis, where do we stand?.

Kammer M, Massion P J Thorac Dis. 2020; 12(6):3317-3330.

PMID: 32642255 PMC: 7330751. DOI: 10.21037/jtd-2019-ndt-10.


References
1.
Wang X, Yu J, Sreekumar A, Varambally S, Shen R, Giacherio D . Autoantibody signatures in prostate cancer. N Engl J Med. 2005; 353(12):1224-35. DOI: 10.1056/NEJMoa051931. View

2.
Gaster R, Hall D, Nielsen C, Osterfeld S, Yu H, Mach K . Matrix-insensitive protein assays push the limits of biosensors in medicine. Nat Med. 2009; 15(11):1327-32. PMC: 4165514. DOI: 10.1038/nm.2032. View

3.
Smith M . Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003; 22(47):7359-68. DOI: 10.1038/sj.onc.1206939. View

4.
Paweletz C, Charboneau L, Bichsel V, Simone N, Chen T, Gillespie J . Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene. 2001; 20(16):1981-9. DOI: 10.1038/sj.onc.1204265. View

5.
Ito K, Smith B, Parashurama N, Yoon J, Song S, Miething C . Unexpected dissemination patterns in lymphoma progression revealed by serial imaging within a murine lymph node. Cancer Res. 2012; 72(23):6111-8. PMC: 3664177. DOI: 10.1158/0008-5472.CAN-12-2579. View